51 related articles for article (PubMed ID: 34543060)
1. What's Next for Sotorasib in NSCLC?
Cancer Discov; 2023 May; 13(5):1033-1034. PubMed ID: 36929750
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Exuberance on Equipoise in Oncology Clinical Trials: Sotorasib as Archetype.
Fojo T; LaRose M; Bates SE
Oncologist; 2024 Apr; 29(4):275-277. PubMed ID: 38498045
[No Abstract] [Full Text] [Related]
3. Why maximum tolerated dose?
Stampfer HG; Gabb GM; Dimmitt SB
Br J Clin Pharmacol; 2019 Oct; 85(10):2213-2217. PubMed ID: 31219196
[TBL] [Abstract][Full Text] [Related]
4. Toxicity From Sotorasib After Immune Checkpoint Inhibitors: A Note of Caution and Reflections of Future Advancements in the Field.
Desai A; Dimou A
J Thorac Oncol; 2023 Oct; 18(10):1265-1267. PubMed ID: 37758343
[No Abstract] [Full Text] [Related]
5. Severe Immune Checkpoint Inhibitor Hepatitis in
Begum P; Goldin RD; Possamai LA; Popat S
JTO Clin Res Rep; 2021 Sep; 2(9):100213. PubMed ID: 34590053
[TBL] [Abstract][Full Text] [Related]
6. Adagrasib Data Create Buzz at ESMO.
Cancer Discov; 2021 Nov; 11(11):2664. PubMed ID: 34607832
[TBL] [Abstract][Full Text] [Related]
7. Spotlight on Sotorasib (AMG 510) for
Zhang SS; Nagasaka M
Lung Cancer (Auckl); 2021; 12():115-122. PubMed ID: 34675734
[TBL] [Abstract][Full Text] [Related]
8. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS
de Langen AJ; Johnson ML; Mazieres J; Dingemans AC; Mountzios G; Pless M; Wolf J; Schuler M; Lena H; Skoulidis F; Yoneshima Y; Kim SW; Linardou H; Novello S; van der Wekken AJ; Chen Y; Peters S; Felip E; Solomon BJ; Ramalingam SS; Dooms C; Lindsay CR; Ferreira CG; Blais N; Obiozor CC; Wang Y; Mehta B; Varrieur T; Ngarmchamnanrith G; Stollenwerk B; Waterhouse D; Paz-Ares L;
Lancet; 2023 Mar; 401(10378):733-746. PubMed ID: 36764316
[TBL] [Abstract][Full Text] [Related]
9. Diverse alterations associated with resistance to KRAS(G12C) inhibition.
Zhao Y; Murciano-Goroff YR; Xue JY; Ang A; Lucas J; Mai TT; Da Cruz Paula AF; Saiki AY; Mohn D; Achanta P; Sisk AE; Arora KS; Roy RS; Kim D; Li C; Lim LP; Li M; Bahr A; Loomis BR; de Stanchina E; Reis-Filho JS; Weigelt B; Berger M; Riely G; Arbour KC; Lipford JR; Li BT; Lito P
Nature; 2021 Nov; 599(7886):679-683. PubMed ID: 34759319
[TBL] [Abstract][Full Text] [Related]
10. Correction to: Sotorasib: First Approval.
Blair HA
Drugs; 2021 Nov; 81(16):1947. PubMed ID: 34687424
[No Abstract] [Full Text] [Related]
11. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Felip E; Altorki N; Zhou C; Csőszi T; Vynnychenko I; Goloborodko O; Luft A; Akopov A; Martinez-Marti A; Kenmotsu H; Chen YM; Chella A; Sugawara S; Voong D; Wu F; Yi J; Deng Y; McCleland M; Bennett E; Gitlitz B; Wakelee H;
Lancet; 2021 Oct; 398(10308):1344-1357. PubMed ID: 34555333
[TBL] [Abstract][Full Text] [Related]
12. Sotorasib as first-line therapy in patients with advanced non-small cell lung cancer with KRAS gene mutations combined with brain metastases: a case report.
Jia X; Liu M; Cheng Z
AME Case Rep; 2024; 8():48. PubMed ID: 38711902
[TBL] [Abstract][Full Text] [Related]
13. Sotorasib: Is Maximum Tolerated Dose Really the Issue at Hand?
Soulières D; Gelmon KA
J Clin Oncol; 2021 Nov; 39(31):3427-3429. PubMed ID: 34543060
[No Abstract] [Full Text] [Related]
14. Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message?
Ratain MJ; Tannock IF; Lichter AS
J Clin Oncol; 2021 Nov; 39(31):3423-3426. PubMed ID: 34543056
[No Abstract] [Full Text] [Related]
15. Sotorasib: First Approval.
Blair HA
Drugs; 2021 Sep; 81(13):1573-1579. PubMed ID: 34357500
[TBL] [Abstract][Full Text] [Related]
16. Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal.
Chour A; Basse C; Lebossé F; Bonte PE; Girard N; Duruisseaux M
Lung Cancer; 2024 May; 191():107789. PubMed ID: 38614068
[TBL] [Abstract][Full Text] [Related]
17. HER2 mediates clinical resistance to the KRAS
Ho CSL; Tüns AI; Schildhaus HU; Wiesweg M; Grüner BM; Hegedus B; Schuler M; Schramm A; Oeck S
Eur J Cancer; 2021 Dec; 159():16-23. PubMed ID: 34715459
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
